Multistage Mesoporous Silicon-based Nanocarriers: Biocompatibility with Immune Cells and Controlled Degradation in Physiological Fluids.

Biana Godin,Jianhua Gu,Rita E Serda,Silvia Ferrati,Xuewu Liu,Ciro Chiappini,Takemi Tanaka,Paolo Decuzzi,Mauro Ferrari
2008-01-01
Abstract:During the last decades, the advancements in micro- and nano- technology have brought tremendous encouragement to the current biomedical research. Porous silicon (pSi) has many interesting properties that are being investigated for diverse biomedical applications, including biomolecular screening, optical biosensoring, drug delivery through injectable carriers and implantable devices, and orally administered medications with improved bio-availability (1,2). There are already several FDA-approved and marketed products based on pSi technology that have found a niche in ophthalmology and another product, based on radioactive 32P-doped pSi, is currently in clinical trials, as a potential new brachytherapy treatment for inoperable liver cancer. Targeted delivery could offer significant toxicity reduction in adjuvant or neo-adjuvant cancer therapies. Our research group has designed and developed a multistage nanocarrier based on the pSi technology, with the potential to overcome the multiple biological barriers encountered in the circulation and efficiently deliver therapeutics to the tumor site (3). Hemispherical disk-shaped particles with a diameter of 1–3 μm have been chosen to enhance the specific recognition and adhesion to vascular targets based on the theory of Decuzzi et al. (4) and Sakamoto et al. (5). Also, the pSi particle (first stage) has been shown to effectively load multiple types of smaller nanoparticles (second stage), such as quantum dots and single-wall carbon nanotubes, thus originating a multistage delivery system (3). The mechanism of action of the multistage system is schematically presented in Figure 1 (3). Figure 1 Schematic presentation of the mechanism of action of multistage pSi nanovectors (3). The multistage delivery system is assembled by loading second-stage nanoparticles (Q-dots and SWNTs, micelles, liposomes, etc.) into the pores of mesoporous silicon microparticles. ... Biocompatibility and biodegradability are the key requirements for any drug delivery carrier. Moreover, in the multistage system biodegradation plays an important role in delivering second-stage nanoparticles to the target site. In the present study we aimed at evaluating how surface modifications of the multistage pSi nanovectors affect these critical parameters.
What problem does this paper attempt to address?